三鑫醫療(300453.SZ):近期公司PTA高壓球囊擴張導管已中選27省聯盟外周血管介入導引通路等4種醫用耗材集中帶量採購項目
格隆匯4月3日丨三鑫醫療(300453.SZ)於近期投資者關係活動表示,公司圍繞內瘻保護深度佈局血管通路研究和血管介入產品開發,已獲得PTA高壓球囊擴張導管等新產品註冊證,作爲具有廣闊的替代進口空間的產品,該產品的上市有望進一步加快國產替代步伐,普惠廣大透析患者。近期,公司PTA高壓球囊擴張導管已中選27省聯盟外周血管介入導引通路等4種醫用耗材集中帶量採購項目,有望通過集採快速實現“以價換量”,帶來市場新突破。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.